Atea Pharmaceuticals, Inc.
AVIR
Positions held
Your positionsAVIR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $413.46M | Enterprise value | $194.41M | Trailing P/E | — | Forward P/E | -3.48 |
| PEG | — | Price / book | 2.03 | Beta | 0.39 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -58.1% | ROA | -36.7% | Debt / equity | 0.00 |
| Current ratio | 8.13 | Free cash flow | -$92.83M | Analyst recommendation | none | Mean target | $9.42 |
| 52w high | $6.45 | 52w low | $2.87 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$32.9M | -$45.4M | -$44.9M | -$42.0M | -$37.2M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.1M | -$48.0M | -$54.9M | -$45.6M | -$41.3M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$158M | -$168M | -$136M | -$116M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$181M | -$193M | -$164M | -$131M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-19 · Atea (AVIR) Q2 2026 Earnings Call Transcript
2026-08-13 · Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
2026-08-12 · Atea Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 · Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-29 · FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
2026-07-29 · Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
2026-07-28 · Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
2026-07-14 · Atea Pharmaceuticals Begins Phase 1 Clinical Trial of Potential Hepatitis E Treatment
2026-07-14 · Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Price (daily)
Full chart · RSI · MACD · patterns